Health disparities: Exploring the ethics of orphan drugs

American Journal of Health-System Pharmacy

Volumn 71, Issue 9, 2014, Pages 692-693

  Kinney, Justin ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ETHICS; HEALTH CARE; HEALTH DISPARITY; HUMAN; LETTER; POLICY; SOCIAL JUSTICE; UNITED STATES; DRUG COST; DRUG MANUFACTURE; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DISPARITY;

DRUG COSTS; HEALTHCARE DISPARITIES; HUMANS; ORPHAN DRUG PRODUCTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907210916     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130348     Document Type: Letter

References (7)

1. U.S. National Library of Medicine. Health disparities. www.nlm.nih.gov/hsrinfo/disparities.html (accessed 2013 Sep 26).
2. Tambuyzer ER. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010; 9:921-9.
3. National Organization for Rare Disorders. 30 years of progress; NORD 30th anniversary timeline. www.rarediseases.org/30th-timeline (accessed 2013 Sep 27).
4. Ulrich LI. Efforts to develop orphan drugs: the FDA experience. Pharm Policy Law. 2010; 12:53-5.
5. Hughes DY. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006; 24:315-6.
6. Simoens ST. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011; 6:42.
7. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005; 31:164-8.